Abstract
This chapter reviews some experimental evidence supporting the classification and distribution of cardiovascular dopamine (DA) receptors, discusses the cardiovascular and renal effects of DA receptor agonists, and addresses the involvement of second messenger systems in mediating some of the changes elicited following activation of specific DA receptors. The effect of DA and several DA analogs on renal blood flow was studied in detail, and the use of several different types of receptor antagonists led to the identification and characterization of a specific receptor for DA. Experiments performed in conscious rats show that selective DA2 receptor antagonists caused increases in plasma aldosterone, but DA1 receptor antagonists had no effect on plasma aldosterone. Several ergot compounds have been shown to possess agonistic action at dopamine receptors. In the presence of both DA1 and DA2 receptor antagonists, DA failed to produce any changes in cAMP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
